Bristol-Myers Squibb (BMS) and Janssen Pharmaceuticals have entered a worldwide alliance to develop and commercialise a Factor XIa (FXIa) inhibitor, BMS-986177, to prevent and treat major thrombotic disorders.

The partners hope to establish a broad development programme for the FXIa inhibitor across various therapeutic indications.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

During the second half of this year, the companies intend to advance the investigational anticoagulant agent into Phase II clinical trials for secondary stroke prevention.

BMS executive vice-president and chief scientific officer Tom Lynch said: “We are proud to partner with Janssen on our shared vision for advancing cutting-edge science to develop potential new treatments such as BMS-986177 for serious cardiovascular disease.

“By combining the strength of our companies’ extensive expertise in the development and commercialisation of cardiovascular treatments, we can maximise the potential of FXIa inhibition.”

BMS-986177 is being developed to minimise the risk of vascular events without increasing the risk of bleeding in people with thrombotic conditions.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“By combining the strength of our companies’ extensive expertise in the development and commercialisation of cardiovascular treatments, we can maximise the potential of FXIa inhibition.”

These conditions include different cardiovascular disorders such as coronary artery disease, strokes and peripheral artery disease.

Janssen research & development global head Mathai Mammen said: “With the addition of a Factor XIa inhibitor programme to our pipeline, Janssen continues to live up to our long-standing commitment of working tirelessly to bring truly transformational therapies to patients worldwide.

“With this new collaboration we have the potential to improve the standard of care for patients with cardiovascular conditions characterised by pathologic thrombosis.”

Janssen will make an undisclosed upfront payment to BMS, which is also eligible for additional milestone payments.

The partners are set to share development costs and commercial profits and losses.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now